Skip to main content
. 2021 Jul 28;13(15):3800. doi: 10.3390/cancers13153800

Figure 2.

Figure 2

Anti-SARS-CoV-2-antibody response (anti spike-protein-trimer antibody titer) in patients with different characteristics. (A) Anti CD38-treatment, (B) CD19+ B lymphocyte count, (C) disease remission status, (D) vaccine type, and (E) age. * indicates p < 0.05.